title: Reply: Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies.
authors.forename: Xavier
authors.initials: X
authors.lastname: Bosch
authors.forename: Marta
authors.initials: M
authors.lastname: Sitges
authors.forename: Montserrat
authors.initials: M
authors.lastname: Rovira
authors.forename: José Tomás
authors.initials: JT
authors.lastname: Ortiz-Pérez
authors.forename: Jordi
authors.initials: J
authors.lastname: Esteve
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects*; D002227:Carbazoles / Q000008:administration & dosage*; D004656:Enalapril / Q000008:administration & dosage*; D005260:Female; D019337:Hematologic Neoplasms / Q000188:drug therapy*; D006801:Humans; D008297:Male; D011412:Propanolamines / Q000008:administration & dosage*; D018487:Ventricular Dysfunction, Left / Q000188:drug therapy* / Q000517:prevention & control*
chemical_list: D000970:Antineoplastic Agents; D002227:Carbazoles; D011412:Propanolamines; D004656:Enalapril